<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01396733</url>
  </required_header>
  <id_info>
    <org_study_id>AMC_THY_001</org_study_id>
    <nct_id>NCT01396733</nct_id>
  </id_info>
  <brief_title>Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid Cancer</brief_title>
  <acronym>RALT</acronym>
  <official_title>Clinical Trial to Evaluate Efficacy of Redifferentiation Therapy Using Alpha-lipoic Acid in Thyroid Cancer Patients With Decreased Radioactive Iodine Uptake</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radioiodine (I-131) therapy is of proven efficacy for treatment of differentiated thyroid
      carcinoma (DTC). However, loss of differentiation in recurrent or metastatic DTC which
      decrease I-131 uptake may decrease the efficacy of I-131 therapy. Therefore, strategies to
      improve I-131 uptake are mandatory. This study is an open label clinical study to evaluate
      the effectiveness of alpha-lipoic acid (ALA) for improving I-131 uptake in recurrent or
      metastatic of DTC with defective I-131 uptake.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increment of radioactive iodine uptake</measure>
    <time_frame>3months after alpha-lipoic acid treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Thyroid</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who will receive 600 mg/day alpha-lipoic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who will receive 1,200 mg/day alpha-lipoic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alpha-lipoic acids</intervention_name>
    <description>alpha-lipoic acid 600 mg/day or 1,200 mg/day 600 mg/day - Three tablets (200mg x 3), one time per day for 3 months 1,200 mg/day - Three tablets (200mg x 3), two times per day for 3 months</description>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_label>High dose group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. aged 20 to 75 years

          2. under birth control, if fertile women

          3. Groups

               -  who received radioactive iodine treatment for recurrent and metastatic thyroid
                  cancer, and did not showed any uptake at post-therapeutic whole body scan

               -  who planned to receive empirical radioactive treatment due to high expected
                  recurrence

        Exclusion Criteria:

          -  allergic to alpha-lipoic acid

          -  severe heart failure, lung disease, or end-stage renal disease

          -  liver function abnormalities (x2.5 above normal limits)

          -  neuropsychologically unstable patients

          -  previous history of drug medication such as oral steroid, digoxin, theophylline,
             carbamazepine, valproic acid, phenobarbital, methotrexate, cyclosporin, tacrolimus
             within 3 months before this recruitment.

          -  who is already taking alpha-lipoic acid for other purpose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae Yong Kim, MD, PhD</last_name>
      <phone>82-2-3010-3249</phone>
      <email>tykim@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Won Bae Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2011</study_first_submitted>
  <study_first_submitted_qc>July 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2011</study_first_posted>
  <last_update_submitted>July 18, 2011</last_update_submitted>
  <last_update_submitted_qc>July 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Won Bae Kim/professor</name_title>
    <organization>Asan Medical Center</organization>
  </responsible_party>
  <keyword>thyroid</keyword>
  <keyword>cancer</keyword>
  <keyword>redifferentiation</keyword>
  <keyword>lipoic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thioctic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

